• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

New (drug) hope for Ross River, dengue fever sufferers

Shiloh

Editor, Senior Moderator
Source: http://www.abc.net.au/news/stories/2009/08/07/2649169.htm

New hope for Ross River, dengue fever sufferers

Posted 9 hours 33 minutes ago
Updated 9 hours 14 minutes ago


Scientists at the University of Canberra (UC) have identified a new drug which could be used to reduce the pain and swelling associated with the Ross River virus, dengue fever and influenza.

Professor Suresh Mahalingam last year helped uncover the proteins which cause serious viral inflammation.

The researchers and a pharmaceutical company have now identified an existing drug which targets those specific proteins and appears to reduce the severity of some inflammatory conditions.

He says tests have been conducted on mice with positive results.

"We've utilised that drug in our model and shown that the drug actually protects the animals from developing arthritic inflammation, tissue damage and therefore the mice do not actually succumb to the disease that badly," he said.

Professor Mahalingam says it is a major breakthrough with global implications.

"Viral inflammation can cause pain and tissue damage. Until now these painful symptoms were treated using broad spectrum anti-inflammatory drugs," he said.

"The problem with these existing drugs is they may attack the good proteins that could otherwise help fight off the virus.


"By first identifying the specific proteins and then finding a drug that targets them, we can reduce pain, inflammation and tissue damage and leave the body to what it does best - fight off the virus."

Professor Mahalingam hopes the drug will be available to the public within three years.


"To identify the proteins that cause the problem was a major step forward. But to find a drug that already targets them and to prove it works, means people around the world will be able to benefit from our research far sooner than if we had to develop a brand new drug."
 
Back
Top Bottom